Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Poland flag Poland · Delayed Price · Currency is PLN
39.30
-1.20 (-2.96%)
Apr 2, 2025, 4:22 PM CET
-37.62%
Market Cap 185.58M
Revenue (ttm) 19.36M
Net Income (ttm) -41.15M
Shares Out 4.66M
EPS (ttm) -8.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,429
Average Volume 5,495
Open 40.50
Previous Close 40.50
Day's Range 39.10 - 40.50
52-Week Range 36.20 - 86.40
Beta 0.72
RSI 39.34
Earnings Date Apr 4, 2025

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 105
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CTX
Full Company Profile

Financial Performance

In 2023, WSE:CTX's revenue was 13.20 million, an increase of 44.15% compared to the previous year's 9.16 million. Losses were -70.58 million, 96.6% more than in 2022.

Financial Statements

News

There is no news available yet.